US’ Food and Drug Administration approved Crispr Therapeutics’ experimental vaccine Casgevy for the treatment of sickle Cell disease, a blood disorder that causes uncontrollable blood clotting. It is the first-ever “gene therapy” to have been approved for use by the US. According to the company’s preliminary results, 90% of patients didn’t require a red-blood-cell transfusion…